Factor Bioscience Celebrates 10th Anniversary with Grand Opening of ISO Class 7 Cleanroom Facility in Cambridge, Massachusetts
09/15/2021 - 08:15 AM
CAMBRIDGE, Mass. , Sept. 15, 2021 /PRNewswire/ -- Factor Bioscience Inc., a biotechnology company headquartered in Cambridge, Massachusetts , celebrated its tenth anniversary on September 9, 2021 with the grand opening of its new ISO Class 7 cleanroom facility at its headquarters near Inman Square. The new facility allows Factor and its strategic partners to produce advanced mRNA, gene-editing, and cell-therapy products for all phases of clinical development.
"This expansion will accelerate the development of important therapeutic applications of our technologies in areas such as anti-inflammatory, anti-cancer, and regenerative medicine," said Factor Co-Founder, Chairman, and CEO, Matt Angel , Ph.D. "This is the culmination of a decade of work by the Factor team and a shared vision between us and our strategic partners."
Dr. Angel was joined by leadership representatives from those partners in a formal ribbon cutting ceremony. In addition to Factor Co-Founder and Chief Technology Officer Christopher Rohde , Ph.D., Gregory Fiore , M.D., Co-Founder and CEO of Exacis Biotherapeutics Inc., and Howard Federoff , M.D., Ph.D., CEO of Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) helped dedicate the new facility.
" We are excited to announce this major step forward," said Dr. Fiore. " Securing a dedicated GMP manufacturing capacity within the Factor facility allows us to produce our unique and high-quality cells on our own timeline as we progress toward the clinic."
" The new mRNA cleanroom facility is an important part of our planned R&D operations, and of strategic advantage as we share the space with Factor Bioscience, from which we have in-licensed critical mRNA gene editing technology," said Dr. Federoff.
About Factor Bioscience Founded in 2011, Factor Bioscience develops technologies for engineering cells to advance the study and treatment of disease. Factor Bioscience is privately held and is headquartered in Cambridge, MA. For more information, visit www.factorbio.com .
Media Contact: Allen Mireles allen.mireles@scistories.com
https://www.prnewswire.com/news-releases/factor-bioscience-celebrates-10th-anniversary-with-grand-opening-of-iso-class-7-cleanroom-facility-in-cambridge-massachusetts-301377011.html
SOURCE Factor Bioscience
Brooklyn ImmunoTherapeutics Inc
NASDAQ:BTX
BTX Rankings
N/A Ranked by Stock Gains
BTX Stock Data
Industry
Television Broadcasting
Sector
Information
Tags
Health Technology, Medical Specialties, Biotechnology
About BTX
Brooklyn is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. The company is also exploring opportunities to advance therapies using leading edge gene editing/cell therapy technology through its option agreements with Factor Bioscience and Novellus.
Brooklyn’s most advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.
